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ABSTRACT
Nucleoside Monophosphate Kinases (NMPKs)
family are key enzymes in nucleotide metabolism.
Bacterial UMPKs depart from the main superfamily
of NMPKs. Having no eukaryotic counterparts they
represent attractive therapeutic targets. They are
regulated by GTP and UTP, while showing different
mechanisms in Gram(+), Gram(–) and archaeal
bacteria. In this work, we have characterized the
mycobacterial UMPK (UMPKmt) combining enzym-
atic and structural investigations with site-directed
mutagenesis. UMPKmt exhibits cooperativity
toward ATP and an allosteric regulation by GTP
and UTP. The crystal structure of the complex of
UMPKmt with GTP solved at 2.5A ˚ , was merely
identical to the modelled apo-form, in agreement
with SAXS experiments. Only a small stretch of
residues was affected upon nucleotide binding,
pointing out the role of macromolecular dynamics
rather than major structural changes in the allo-
steric regulation of bacterial UMPKs. We further
probe allosteric regulation by site-directed muta-
genesis. In particular, a key residue involved in the
allosteric regulation of this enzyme was identified.
INTRODUCTION
The growing number of infectious bacteria with multiple
drug resistance mechanisms urges the discovery of new
drugs with original mechanism of action (1). This is par-
ticularly the case for Mycobacterium tuberculosis, which
remains a major public health issue. Current treatment
requires a therapy involving four different drugs and for
a period of 6–9 months. This often leads to poor patient
compliance and subsequently to drug resistance (2).
Indeed, multi-drug resistant tuberculosis (MDR-TB)
emerged in the early 1990s and extensively drug-resistant
tuberculosis (XDR-TB) cases were ﬁrst reported in 2005
(3,4). Consequently, a renewed effort to develop new
anti-tuberculosis drugs is necessary (5–7). Accordingly,
new therapeutic targets are to be precisely characterized
to uncover their speciﬁc structural and functional features
(8–10).
Large-scale structural genomic projects have been
launched to provide X-ray or nuclear magnetic resonance
(NMR)-derived structures to help functional annotation
and virtual screening (11). Nevertheless, the extent to
which each target from a given pathogen should be
characterized has to be deﬁned. This is particularly true
for 3D-structure determination. NMR and X-ray crystal-
lography are efﬁcient and can provide structures at atomic
resolution. However, various bottlenecks exist, such as
over-expression, stabilization or crystallisation that slow
down the experimental characterization of many targets.
In the case of M. tuberculosis, despite some signiﬁcant
improvement in the last decade, many proteins remain
refractory to structural analysis (11). Sequence compari-
sons and molecular modelling have been suggested as an
alternative for quicker structural annotation at the
expense of the overall quality and precision. However,
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despite good sequence conservation. These variations are
still difﬁcult to predict.
The multi-faceted limits of functional and structural an-
notations by means of sequence comparisons can be
illustrated with the studies of nucleoside monophosphate
kinases (NMPKs). The NMPKs are essential enzymes and
represent attractive therapeutic targets. They catalyze the
phosphorylation of nucleoside monophosphate into nu-
cleoside diphosphate using ATP as the main phosphoryl
group donor. Structure determination and sequence com-
parisons led to the deﬁnition of two main classes of
NMPKs. Members from four out of the ﬁve functional
families (AMP kinase (AMPK), GMP kinase (GMPK),
CMP kinase (CMPK) and TMP kinase (TMPK)) belong
to class-I. All the enzymes of this class share a common
overall fold related to the Rossmann fold (12) and contain
a strictly conserved P-loop (13). These similarities sug-
gested that the ﬁrst structures of AMPKs solved would
be useful for modelling most other NMPKs. These
class-I enzymes are usually small ( 200 residue long)
and monomeric, sharing a structurally common catalytic
centre (14,15). This common binding site could be
recognized from sequence comparisons despite large
sequence divergence (16,17) and they appear to all accom-
modate their phospho-donor in a similar orientation.
However, some structural variations exist and have
usually evolved according to substrate speciﬁcity. The par-
ticular sub-domain organization observed in CMPK could
be also predicted (18,19) but the speciﬁc dimerization of
TMPK was only revealed by resolution of an X-ray struc-
ture (20). Surprisingly, eukaryotic UMP/CMPK are
bifunctional type-I NMPKs as they efﬁciently phosphor-
ylate CMP as well as UMP. Conversely, many of the
structural features of type-I NMPKs could not be found
in the bacterial UMPKs, which constitute the second class
of NMPKs.
Bacterial UMPKs do not belong to the P-loop contain-
ing kinases but rather to the superfamily of amino acid
kinases (AA-kinases, PF00696) (21). They feature a
Kx38-42GggN motif instead of a classical P-loop motif
(Gx4GKt). They also differ from class-I NMPKs in their
overall topology and multimeric organization. Slightly
larger ( 240 residues) and usually hexameric, they still
adopt a Rossman fold decorated with additional second-
ary structures or subdomains. A model of the monomer
structure was ﬁrst deduced from the distantly related and
mainly dimeric AA-kinases (22,23). A common binding
site accommodating the phospho-donor (ATP) could be
detected and the rough orientation of the UMP was also
extrapolated. A more precise view of the substrate binding
and quaternary structure came from the ﬁrst crystal struc-
tures of an UMPK (24–26). Sequence comparisons
allowed extending these structural features to all bacterial
UMPKs.
Within this context, the studies of the mycobacterial
NMPKs revealed peculiar and surprising variations.
Sequence analyses suggest that a recent divergence
occurred from a bacterial genetic background (27). The
mycobacterial genomes (28–31) encode ﬁve NMPKs
with distinct and original sequence evolution trends.
AMPK from Mycobacterium tuberculosis (AMPKmt,
Rv0733) represents a new subfamily of short bacterial
enzymes (32). Nevertheless, AMPKmt is  47% identical
to its bacterial orthologues while eukaryotic enzymes are
slightly more distant in sequence ( 36%). This sequence
conservation was conﬁrmed at the structural level by
NMR (33,34). On the contrary, GMPK from M. tubercu-
losis (Rv1389) is (slightly) more closely related to the eu-
karyotic enzymes than their bacterial orthologues. Its
crystal structure revealed that it is similar in several but
not all respects to its eukaryotic counterparts. Indeed its
GMP binding site is unique (35). A more complex evolu-
tion is illustrated with the TMPK from M. tuberculosis
(TMPKmt, Rv3247c), which was shown to be a chimera
of prokaryotic and eukaryotic enzymes (36). In this case,
modelling at low level of sequence identity (23%) was
sufﬁcient to identify a new substrate, although the
enzyme inhibition by AZT could not be explained by
this method. Based on the X-ray structures, different
families of nucleosidic and non-nucleosidic analogues
were derived to target TMPKmt (37–43). Some of them
proved to have inhibitory activity on mycobacterium
growth without cytotoxic effects on human cells (40,43).
These data conﬁrm the importance of NMPKs as poten-
tial therapeutic targets for antimycobacterial compounds.
The last two mycobacterial NMPKs (CMPK and
UMPK) are clearly prokaryotic enzymes. Indeed, a
functional CMPK (Rv1712) closely related to its bacter-
ial orthologues ( 40%) was recently described in
M. tuberculosis (44). It efﬁciently phosphorylates CMP
(and dCMP) but UMP very poorly. In parallel, the myco-
bacterial genome encodes for Rv2883c (named herein,
UMPKmt) exhibiting  50% identity with bacterial
UMPKs.
Here, we describe the catalytic and regulatory properties
of recombinant UMPKmt overexpressed in Escherichia
coli. We have combined biochemical characterization,
comparative modelling and, subsequently, X-ray crys-
tallography with directed mutagenesis to unravel the
functional features of this enzyme.
MATERIALS AND METHODS
Chemicals
Restriction enzymes, T4 DNA polymerase and coupling
enzymes for determination of UMPK activity were
purchased from Roche Applied Science. T4 DNA ligase
and Vent DNA polymerase were purchased from New
England Biolabs, Inc. BD TALON metal afﬁnity resin
was purchased from BD Biosciences Clontech. ATP,
GTP, UTP, dUTP, dGTP and dTTP were purchased
from Sigma. 5F-UMP, 5Br-UMP, 5F-UTP, 5I-UTP,
aminoallyl UTP, 8Br-GTP, Mant-GTP, 6-methylthio
GTP, GMPPCP and GMPPNP were purchased from
Jena Bioscience. NDP kinase was kindly provided by I.
Lascu.
Bacterial strains and growth conditions
The E. coli NM554 (45) and BL21(DE3)/pDIA17 (46)
strains were used for DNA puriﬁcation and for
Nucleic Acids Research,2011, Vol.39, No. 8 3459production of recombinant wild-type and variant
UMPKmt, respectively. Cultures were grown in 2YT
medium (47) supplemented with 100mg/ml ampicillin or
70mg/ml kanamycin and 30mg/ml chloramphenicol.
Production of recombinant UMPKmt was induced with
isopropyl-1-thio-b-D-thiogalactoside (1mM ﬁnal concen-
tration) when cultures reached an absorbance of 1.5 at






genomic DNA as the matrix. During ampliﬁcation, NdeI
and HindIII restriction sites were created at the ends of the
ampliﬁed fragment. After digestion by NdeI and HindIII,
the ampliﬁed pyrH gene was inserted into the pET22b and
pET28a plasmids (Novagen, Inc.) digested with the same
enzymes. Three clones containing the M. tuberculosis pyrH
gene and overexpressing UMPKmt with or without a N-
terminal end his-tag were characterized and one of them
(harbouring plasmid named pHL60-3 and pHL60,
respectively) was kept for further studies.
Site-directed mutagenesis
Site-directed mutagenesis was performed by PCR on
plasmid pHL60-3 in two steps using for each variant the
T7 promotor and terminator primers and two mutant
oligonucleotides. Sequences of mutated oligonucleotides
were: 50- CGGCAACTTTTGGCGGGGCGCA-30 and
50-TGCGCCCCGCCAAAAGTTGCCG-30 for the
F81W variant (corresponding plasmid: pHL60-303),
50-GGCAACTTTTTCCATGGCGCACAGC-30 and
50-GCTGTGCGCCATGGAAAAAGTTGCC-30 for the
R82H variant (corresponding plasmid: pHL60-301), 50-C
CGTACCTGTGGTTGCGGGCC-30 and 50-GGCCC
GCAACCACAGGTACGG-30 for the P139W variant
(corresponding plasmid: pHL60-302), 50-CCGTACCTC
CATTTGCGGGCC-30 and 50-GGCCCGCAAATGGA
GGTACGG-30 for the P139H variant (corresponding
plasmid: pHL60-304) and, 50-CCGTACCTGGCCTTGC
GGGCC-30 and 50-GGCCCGCAAGGCCAGGTA
CGG-30 for the P139A variant (corresponding plasmid:
pHL60-305). They were designed either to create or to
destroy a restriction site. The double mutant F81W
S96A (corresponding plasmid pHL60-306) was obtained
using the same procedure but with the pHL60-303 plasmid
as the matrix and the following mutated oligonucleotides
50-GAGCGCACCAGGGCGGACTATATGGGA-30 and
50-TCCCATATAGTCCGCCCTGGTGCGCTC-30. The
last two mutants were constructed by the one-tube
PCR-based mutagenesis method (48) with the following
mutagenic oligonucleotides: 50-CTCCAGGAAGGCTTG
CAGTGCAAG-30 for the D113A variant (corresponding
plasmid: pHL60-307) and 50-CACCTGGAGAAGGGAG
CGGTGGTGATCTTCG-30 for the R150A variant (cor-
responding plasmid: pHL60-308). For each mutagenesis,
the pyrH gene was cloned into the pET28a vector and
sequenced to check for the absence of any other mutation.
Puriﬁcation and activity assay of UMPK from
M. tuberculosis
Bacterial pellets expressing recombinant UMPKmt were
suspended in 50mM sodium phosphate pH 8, 0.1M
NaCl and 5mM imidazole (buffer A) and disrupted by
sonication. After centrifugation at 10000g for 45min, the
soluble extract was added to BD TALON resin (1ml of
resin equilibrated in buffer A per 10mg of recombinant
protein) and gently stirred at room temperature on a
platform shaker. The further steps are described by BD
Biosciences in the Batch/gravity-Flow column puriﬁcation
section (49). Fractions containing UMPKmt were immedi-
ately dialyzed against 20mM sodium phosphate pH 8 and
0.1M NaCl (buffer B) using Spectra/Por membrane with a
molecular weight cut-off of 12–14kDa. The same protocol
was used for the variants of UMPKmt, which were also
expressed as histidine-tagged proteins on their N-termini.
When used for crystallization assays, UMPKmt was
further puriﬁed by gel ﬁltration chromatography on a
HiLoad
TM 26/60 Superdex
TM 200 prep grade (GE
Healthcare). The puriﬁed protein was concentrated up to
12mg/ml in buffer B using a 50K stirred cell system (Pall
Life Sciences) and stored at  20 C.
UMPKmt activity was determined at 30 C using a
coupled spectrophotometric assay (0.5ml ﬁnal volume)
on an Eppendorf ECOM 6122 photometer (50). The
reaction medium contains 50mM Tris–HCl pH 7.4,
50mM KCl, 1mM phosphoenolpyruvate, 0.2mM
NADH, 2U of each lactate dehydrogenase, pyruvate
kinase and NDP kinase, and various concentrations of
ATP, GTP, UTP and UMP. A 2mM excess of MgCl2
over the concentrations of NTPs was selected to ensure
over 95% of NTPs appeared in the Mg-complexed form
and that the free metal was held at a sufﬁciently high
(between 1.8 and 2.8mM) but not inhibitory concentra-
tion (51). UMPKmt diluted in buffer B was then added
and the decrease in absorbance recorded at 340nm. One
unit of enzyme activity corresponds to 1mmol of the
product formed in 1min at 30 C and pH 7.4.
Experimental data were ﬁtted using the Kaleidagraph
software according to the Michaelis–Menten equation




nH), where v is the reaction rate, Vm
the maximal rate, [S] the ATP concentration, Km the
Michaelis–Menten constant, K0.5 the ATP concentration
at half-saturation, and nH the Hill number, indicating the
cooperativity index.
The thermal stability was studied by incubating aliquots
of 1mg/ml protein in buffer B at a temperature between 35
and 80 C for 10min, after which residual activity was
determined. Tm corresponds to the temperature at which
the protein exhibits 50% of its activity.
Equilibrium sedimentation
The experiments were performed at 20 C on a Beckmann
Optima XL-A analytical centrifuge using an An-60 Ti
rotor and a cell with a 12mm optical path length.
Samples (150ml) in buffer B at  0.5mg/ml were
centrifuged at 20000 and 25000r.p.m. Radial scans of
absorbance at 280nm were taken at 2h intervals.
3460 Nucleic Acids Research, 2011,Vol.39, No. 8Equilibrium was achieved after 14h. Data were analysed
by the XL-A program supplied by Beckman. The partial
speciﬁc volume of UMPKmt was calculated from the
sequence (52).
Molecular modelling
UMPKs were manually aligned using ViTO (53). Crude
models were obtained using SCWRL3.0 (54) for the
monomers in various conﬁgurations depending on the
template complexation state. Hexameric models were
built using the same templates and the program
MODELLER 7v7 (55). The same procedure was applied
for the wild-type and the mutant enzymes. Various tem-
plates were combined to build models of UMPKmt in
complex with its natural ligands. The whole procedure
(comparative modelling and ligand docking by similarity)
can now be performed on the ﬂy using the Web-server
@TOME-2 (56) as exempliﬁed with UMPKmt (http://
atome.cbs.cnrs.fr/AT2/EG/3675/atome.html).
Crystallization and X-ray data collection
Crystallization was obtained in the presence of a high con-
centration of sodium/potassium tartrate (1.2M) at pH 7.4,
and of 10mM GTP. X-ray diffraction data sets were col-
lected from frozen single crystals at the European
Synchrotron Radiation Facility (Grenoble, France,
beamline ID14-4) and processed with the programs
MOSFLM, SCALA and TRUNCATE from the CCP4
program suite (57).
The structure was solved by molecular replacement
using the program MolRep (58) and the crystal structure
of UMPK from Streptococcus pyogenes (PDB1Z9D; to be
published) as a search model. Model reﬁnement was per-
formed using the program COOT (59) and the program
REFMAC5 (60), using a translation/liberation/screw
model (61) against the GTP-bound data set at 2.8A ˚ and
then at 2.5A ˚ resolution (Table 1). In the ﬁnal model, short
segments of the protein were not clearly visible in the
electron density map. Most of the histidine-tag, the ﬁrst
28 residues, as well as a short stretch lying in the
ATP-binding site (residues 206–210) could not be
modelled in the electron density.
Small-angle X-ray scattering experiments and data
analysis
Synchrotron X-ray scattering data from solutions of
UMPKmt were collected on the SWING beamline of
the Soleil Synchrotron (Saint-Aubin, France) using a
PCCD-170170 detector at a wavelength of 1.03A ˚ . The
scattering patterns were measured by merging 10–20
data recordings with 1-s exposure time each, for two
solute concentrations (1.825 and 5.25mg/ml). To check
for radiation damage, all successive exposures were
compared, and no changes were detected. Using the
sample-detector distance of 1.8m, a range of momentum
transfer of 0.0065<s<0.6A ˚  1 was covered (s=4psin(q)/
l, where 2q is the scattering angle, l is the X-ray wave-
length). The data were processed using standard proced-
ures and extrapolated to inﬁnite dilution using the
program PRIMUS (62). The forward scattering, I(0),
and the radius of gyration, Rg, were evaluated using the
Guinier approximation, assuming that at very small angles
(s<1.3/Rg) the intensity is represented as I(s)=I(0)
exp( s
2Rg
2)/3). The values of I(0) and Rg, as well as the
maximum dimension, Dmax, and the interatomic distance
distribution functions, [p(r)], were also computed using the
program GNOM (63).
Other analytical procedures
Protein concentration was measured according to
Bradford (64), using a Bio-Rad kit or by amino acid
analysis on a Beckman system 6300 high-performance
analyser after 6N HCl hydrolysis for 22h at 110 C.
SDS-PAGE was performed as described by Laemmli (65).
RESULTS
Overproduction, puriﬁcation and molecular
characterization of UMPKmt
The wild type UMPKmt was overproduced in large
quantities in E. coli strain BL21(DE3)/pDIA17 (46) and
it amounted between 25% and 30% of soluble E. coli





Space group P212121 P21212
Cell dimension a, b, c (A ˚ ) 123.4, 139.3, 183.7 136.7, 175.5, 65.4
No. molecules in a.u 1 1
Wavelength (A ˚ ) 0.9334 0.91850






a,b 7.9 (57.0) 4.4 (58.3)
I/sI
a 8.5 (1.5) 12.2 (0.8)
Completeness (%)
a 100. (100.) 90.8 (61.4)
Redundancy
a 3.9 (4.0) 4.2 (2.5)
B-wilson 35.2 53.4
Reﬁnement
Resolution (A ˚ ) 2.9 2.49
No. Reﬂections 18685 43188
Rwork/Rfree (%)
c,d 23.0/26.2 22.0/27.3
No. protein atoms 4175 2065
No. water molecules – 98
Ligand type 12 GTP 6 GTP
1 UDP






Bond lengths (A ˚ ) 0.009 0.009
Bond angles ( ) 1.40 1.6
aValues in parentheses refer to the outermost resolution shell.
bRmerge=hkli|Ihkl,i – Iaverage,hkl|/|hkli|Ihkl,i| x100.
cRwork=hkl|Fobs – Fcalc|/hkl |Fobs| x100.
dRfree is calculated in the same way on a subset of reﬂections that are
not used in the reﬁnement (5%).
eDeviation from ideal values.
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differences in the speciﬁc activity between His-tagged and
non-tagged forms of UMPKmt, the His-tagged enzyme
puriﬁed by afﬁnity chromatography on BD TALON
resin (BD Biosciences) was used exclusively in further ex-
periments. Similar conclusions were reached with recom-
binant UMPKs from E. coli, Haemophilus inﬂuenzae or
Bacillus subtilis (51). The purity of UMPKmt was over
95% as indicated by SDS-PAGE.
The molecular mass of the native protein, determined
by sedimentation equilibrium ultracentrifugation
(173170±3161Da), corresponds to a hexamer. This is
consistent with the quaternary structure observed for
other bacterial UMPKs (51,66,67). The pure enzyme was
stored at 4 C in 20mM phosphate (pH 7) and 100mM
NaCl with no apparent loss of activity for  2 months.
Thermal denaturation experiments indicated Tm values
of 60 C in the absence of nucleotides and 65 C and
75 C with 1mM GTP and UTP, respectively. In this
respect UMPKmt exhibits a lower thermal stability than
the other NMPKs from the same organism (32,36).
Dependance of UMPKmt activity on various nucleotides
acting as substrates or as allosteric effectors
The plot of UMPKmt activity at variable concentrations
of ATP and saturating concentrations of UMP (1mM or
over) was sigmoidal (Figure 1). Ten separate experiments
using different preparations of UMPKmt yielded an
average value of Vm of 30±1U/mg of protein, K0.5 of
2.2±0.1mM and nH of 1.8±0.2 (Table 2). These
numbers compare well with those observed with UMPK
from Staphylococcus aureus, a Gram-positive bacterium
(51). Among the other nucleoside triphosphates, only
dATP acted as a phosphate donor with reaction rates
similar to that exhibited by ATP. On the contrary, CTP,
UTP or dTTP were not substrates, while the reaction rates
with GTP represented only 0.1% of that with ATP or
dATP. At saturating concentrations of Mg-ATP (5mM
or over), the reaction rate of UMPKmt as a function of
UMP concentration obeys the Michaelis–Menten
equation with an average value from 10 separate experi-
ments of Km
UMP=19.6±1.8mM and Vm=34.8±
0.8U/mg (Table 3). Addition of a ﬂuoro group at the
5-position of the base moiety does not affect the Km and
the Vm of UMPKmt. On the other hand, 5Br-UMP and
dUMP were not substrates of UMPKmt, but acted as
weak competitive inhibitors (Ki>1mM).
GTP and UTP were explored as potential allosteric ef-
fectors. At constant concentrations of ATP and UMP
(1mM each), GTP increased the reaction rate by a
factor of 3.5, with half-saturation at 0.1mM (data not
shown). Conversely, UTP behaved as an inhibitor with
IC50 at 0.1mM (data not shown). Neither the activation
by GTP nor the inhibition by UTP were affected by the
concentrations of UMP (between 5mM and 2mM) or
MgCl2 (between 3 and 20mM). As it has been stated
that the two effector binding sites were identical or
largely overlapping in Gram-positive bacteria (51), the
UMPKmt activity was measured at a constant concentra-
tion of UTP and at increasing concentrations of GTP
(Figure 2A) and vice versa (Figure 2B). The inhibition
by 0.5mM UTP was cancelled in the presence of 2mM
GTP, whereas the activation by 0.5mM GTP was reversed
by addition of 1mM UTP. In the following experiments,
we explored the effect of GTP and UTP on kinetics of
UMPKmt with ATP as variable substrate (Figure 1).
GTP decreased both the cooperativity and the apparent
K0.5 for ATP, whereas UTP exhibited the opposite effect
by increasing both the nH and the K0.5 for ATP. Several
GTP and UTP analogues were tested for their ability to
mimic the action of natural nucleotides. dGTP,
Mant-GTP and 6-methylthio GTP exhibited similar
properties to GTP in terms of both afﬁnity and extent of
activation. GMP-PNP and GMP were much weaker acti-
vators (only 50% and 30% increase in activity at 1 and
2.5mM nucleotide, respectively), whereas GMP-PCP and
8Br-GTP were ineffective. Among UTP analogues,
5I-UTP was the strongest inhibitor (IC50=0.02mM)
followed by 5Br-UTP, dUTP and dTTP (IC50=0.1,
0.24 and 0.4mM, respectively). 5F-UTP exhibited a
biphasic effect. Below 0.15mM it increased the activity
of UMPKmt by 80%. Over this concentration it became
inhibitory. For example, at 0.6mM 5F-UTP, the enzyme
activity is decreased by 40%.
Molecular modelling of UMPKmt
With the exception of a 28-residue long extension at its
N-terminus, the UMPKmt sequence appeared highly
similar to those of other bacterial UMPKs, showing up
to 50% of identity over 240 residues (Figure 3). The
speciﬁc N-terminal extension is predicted to be ﬂexible
and unfolded due to its strong composition bias in small
residues (mainly G, A, P). By using templates from other
bacterial UMPKs, we have built models of UMPKmt in
various conﬁgurations (see ‘Materials and Methods’
section). In addition, the conserved quaternary hexameric
structure was modelled using multimeric templates and
taking into account crystal symmetry when necessary.
Figure 1. UMPKmt activity versus Mg-ATP concentration. Enzyme
activity was determined at a ﬁxed concentration of UMP (2mM),
and, in the absence (ﬁlled square) or in the presence of effectors
(0.5mM GTP: ﬁlled circle and 0.1mM UTP: diamond-shaped). The
curves correspond to the ﬁt of the experimental data to the Hill
equation and the calculated parameters are displayed in Table 2.
3462 Nucleic Acids Research, 2011,Vol.39, No. 8Using the structures of several bacterial UMPKs in
complex with their common ligands (UMP and UDP)
(24,68), the ligand-binding mode and the accompanying
structural rearrangements could be analysed. Similarly,
the mode of recognition of ATP could be deduced
using its structure bound to archeal UMPKs (26) or to
the more distantly related AA-kinases as previously
described (23).
The ATP binding site is rather well conserved in
sequence and structure among the bacterial UMPKs and
also the distantly related aspartokinases and glutamate
kinases (25,26,68–70). In this AA-kinase superfamily, it
is formed solely by residues from the C-terminal region
(residues 170–261 in UMPKmt) from one monomer and
contains no residues protruding from other monomers.
Several conserved motifs were previously described
(23,69) suggesting that the orientation of the phosphate
donor is conserved for all these kinases. This conclusion
is in agreement with the archaeal UMPK crystal structures
determined in complex with ATP or an analogue (25,26).
Among these sequence motifs, the DgvyxxDP (upper
case stands for strictly conserved residue, lower case
for conserved residue and x for any amino acid;
188-DGVFAEDP-195 in UMPKmt) contributes to the
speciﬁc recognition of the adenosine nucleobase.
The binding site of the phosphate acceptor (UMP) was
modelled in two different conformations depending on the
presence of a bound ligand in the template. It is mainly
composed of residues from the N-terminal part including
three different regions. First, a common glycine-rich loop
(76-GGGN-79 in UMPKmt) is involved in the recognition
of the a-phosphate group of UMP. The conformation of
this loop is stabilized by two conserved asparagines (N79
and N107 in UMPKmt). Their side-chains, facing each
other, form intertwined hydrogen bonds. The second
part of the UMP binding site is composed of the
conserved motif 157-GmGxPyFsTD-166 in UMPKmt
(the last two residues of this motif participate in the cata-
lytic centre as discussed below) and is involved in the rec-
ognition of the base moiety. Two hydrogen bonds are
formed between the nucleobase and the protein
backbone according to the structure of the E. coli
UMPK in complex with UMP (24). In addition, van der
Waals interactions are observed between the pyrimidine
ring and the backbone of the conserved P161 and F163
of the motif. As in Gram-positive UMPKs, a hydrophobic
residue is also present in this region in UMPKmt (M158)
while Gram-negative and archaeal enzymes possess a
threonine. The latter is hydrogen-bonded to a carbonyl
of the uridine moiety. While the conformations of the
ﬁrst two regions of the UMP binding site seem rigid and
little affected by the presence UMP or UDP, the last
region (81-fRGxxlxxxg-90) seems rather ﬂexible. It is
observed in distinct conformations or orientations in the
various crystal structures solved so far (see below).
The catalytic site is centred around a conserved and
buried lysine (K36 in UMPKmt). This lysine and the
three conserved glycines (G76, G77 and G78), which con-
stitute the ﬁrst region of the UMP binding site, form a
sequence motif speciﬁc for bacterial UMPKs. The lysine
side-chain lies in the vicinity of two strictly conserved
polar residues (T165 and D166 in UMPKmt and belong-
ing to the second region of the UMP binding site). A
conserved glutamate (E40 in UMPKmt) is located in the
Table 2. Kinetic parameters of wild-type and variants UMPKmt with Mg-ATP as variable substrate
Enzyme variant No effector With GTP With UTP
Vm (U/mg) K0.5 (mM) nH Vm (U/mg) K0.5 (mM) nH Vm (U/mg) K0.5 (mM) nH
Wild type (1.0; 0.2) 30.0±1.0 2.2±0.1 1.80±0.15 30.7±1.3 1.2±0.1 1.02±0.08 28.4±0.6 4.7±0.1 2.42±0.11
F81W (1.0; 1.0) 12.1±0.6 2.9±0.3 1.17±0.07 12.4±1.4 2.2±0.7 1.04±0.19 8.7±0.4 3.2±0.3 1.99±0.22
F81W S96A (2.0; 0.2) 4.1±0.4 4.1±0.6 1.91±0.27 5.1±0.4 2.2±0.4 1.16±0.13 3.5±0.2 4.9±0.3 2.05±0.13
R82H (2.0; 0.2) 0.30±0.01 3.3±0.3 1.07±0.05 0.30±0.01 3.6±0.4 1.36±0.11 0.20±0.01 3.9±0.2 2.14±0.16
P139W (0.5; 0.5) 14.1±0.4 0.8±0.1 0.99±0.07 14.2±0.9 0.5±0.1 1.05±0.20 14.4±1.8 1.5±0.5 1.05±0.23
P139H (2.0; 0.5) 21.9±3.1 10.6±3.1 0.96±0.06 23.8±0.8 0.8±0.1 0.96±0.08 nf nf nf
P139A (1.0; 1.0) 35.1±3.8 3.3±0.9 1.04±0.11 39.0±4.0 3.3±0.8 1.01±0.11 26.2±2.1 3.1±0.4 2.01±0.36
D113A (0.5; 0.5) 38.4±2.3 2.2±0.3 1.01±0.07 33.2±1.7 2.3±0.2 1.16±0.07 32.5±2.5 3.3±0.4 1.61±0.17
R150A (0.5; 0.2) 7.1±0.5 1.5±0.2 1.42±0.15 7.4±0.6 0.5±0.1 0.92±0.14 5.5±0.7 4.4±0.9 1.38±0.15
nf: not ﬁtted
Reaction rates were determined at a constant concentration of UMP (2mM) and in the absence or in the presence of the effectors (GTP and UTP
concentrations are given into brackets near the name of the enzyme variant, respectively) and ﬁtted according to the Hill equation (see under
‘Materials and Methods’ section).
Table 3. Kinetic parameters of wild-type and variants UMPKmt with
UMP as variable substrate











Reaction rates were determined at a constant concentration of Mg-ATP
(5mM) and ﬁtted according to the Michaelis–Menten equation (see
under ‘Materials and Methods’ section).
Nucleic Acids Research,2011, Vol.39, No. 8 3463Figure 3. Sequence-structure alignment of bacterial UMPKs. UMPK sequences from four Gram-positive bacteria (M. tuberculosis (MtUMPK)
reported in this work, Streptococcus pyogenes (SpUMPK, PDB code 1Z9D), S. aureus (SaUMPK), B. anthracis (BaUMPK, PDB code 2JJX)),
from the small genome size organism Ureaplasma parvum (UpUMPK, PDB code 2VA1) and from four Gram-negative bacteria [E. coli (EcUMPK,
PDB codes 2BND, 2BNE, 2BNF and 2V4Y), H. inﬂuenzae (HiUMPK, code 2A1F), Neisseiria meningitidis (NmUMPK, PDB code 1YBD),
X. campestris (XcUMPK, PDB codes 3EK5 and 3EK6)]. The PDB codes of the 3D-structures used for the UMPKmt modelling are also indicated
next to the UMPK acronyms. The secondary elements for UMPKmt are shown over the alignment. The ﬁrst 23 residues of UMPKmt were omitted
as they are not conserved in sequence and not seen in the 3D-structure. Strictly conserved residues in all sequences are boxed in black and conserved
residues in eight sequences out of nine are bordered. The consensus sequence (>90%) is provided under the sequence alignment: upper case stands
for strictly conserved residue, lower case for conservatively substituted residue, ‘slash’ and ‘hash’ for any hydrophobic or polar residues, respectively.
Residues modiﬁed by site-directed mutagenesis are indicated by black triangles (single substitutions at positions F81, R82, D113 and R150), asterisk
(substitutions at the position P139) and grey triangle (second position of the double mutant F81W, S96A).
Figure 2. Effect of the effectors on UMPKmt activity. (A). Enzyme activity was determined at ﬁxed concentrations of substrates (5mM Mg-ATP
and 2mM UMP) in the absence (ﬁlled circle) or in the presence (ﬁlled square) of 0.5mM UTP. Each data point represents a single determination.
(B). Same as (A) but with GTP as the effector.
3464 Nucleic Acids Research, 2011,Vol.39, No. 8vicinity of the transferred phosphate group and interacts
in some crystal structures with the conserved R82
(UMPKmt) lying on the top of the UMP binding site.
According to this comparative analysis of the known
crystal structures, the catalytic centre appears partially
ﬂexible and shows a small induced-ﬁt while lying
in-between the two substrate binding sites (ATP and
UMP, respectively).
Molecular modelling was sufﬁcient to recognize the
ATP and UMP binding sites and to explain the speciﬁcity
of recognition. Conversely, the effector binding sites could
not be ascertain although a cluster of positively charged
residues was observed at the trimer interface. A similar
situation was recently observed in two UMPKs from
Gram-negative bacteria (E. coli and Xanthomonas
campestris) (71,72). Despite a good overall sequence con-
servation, local variations suggested a distinct mode of
GTP recognition between the E. coli UMPK and
UMPKmt. The recent structure of the GTP-bound
UMPK from X. campestris (72) showed an alternative
conformation of the GTP molecules. The latter resembles
that of the ATP molecules in the allosteric binding pocket
in the B. anthracis UMPK (68). This new mode of binding
seemed more compatible with the expected allosteric
pocket in UMPKmt. The observed variations prompted
us to solve the experimental structure in complex with one
of the allosteric regulators.
Crystal structure of UMPKmt in complex with GTP
Crystallization was achieved in the presence of GTP, at
high concentration of tartrate at a mild basic pH and in
the presence of GTP. In the same crystallization condi-
tions UTP prevents crystal growth. The structure was
solved by molecular replacement. Two hexamers were
observed in the asymetric unit (data not shown) and the
electron density map at 2.9A ˚ resolution was sufﬁcient to
identify the position of six GTP molecules bound along
the 3-fold axis of the protein. Attempts to soak the crystals
with 5I-UTP led to a better diffracting crystal (to 2.5A ˚
resolution). The latter contains only one hexamer
in a half-sized asymmetric unit (Table 1). This new
crystal structure was reﬁned to a 2.5-A ˚ resolution using
REFMAC5 with TLS simulating rigid-body movement of
each monomer. The overall structure is merely identical to
that of other known UMPKs (Figures 4A and S1). The
monomer showed a conserved topology (RMSD ranging
from 0.7 to 1.3A ˚ ) and the hexamer adopted the same
overall organization in agreement with the high global
sequence identity (40–50% for the closest crystal
structures).
The long N-terminal extension (residues 1–28) is not
visible in the electron density. The helical segment 81–89
appeared ﬂexible in two monomers and residues 81 to 84
could not be traced convincingly in the electron density.
The large loop (residue 192–202) of the complete ATP
binding site could only be built in one monomer and its
stabilization is likely due to crystal packing. Overall, the
six monomers adopt a highly similar conformation with
the exception of the helical segment 81–89 and the long
ATP-binding loop in the C-terminal domain. The
hexameric UMPKmt appeared to bind six GTP and one
UDP molecules. No trace of iodide-containing compound
could be detected in any nucleotide-binding sites and at
any step of the reﬁnement (even at 1s in the difference
map of the electron density). Thus, the crystal structure
corresponds to an ‘activated’ form due to the binding of
the positive allosteric effector GTP with ﬁve monomers in
an ‘open’ conformation and one monomer in a ‘closed’
one due to UDP binding. While the ‘opened’ monomers
showed an RMSD of  0.6A ˚ with each other, the differ-
ence rises to  0.8A ˚ with the closed one.
The UDP molecule is observed in the UMP binding site
(Figures S2 and S3) and its orientation perfectly matches
that observed in the UDP-bound UMPKec (PDB2BND).
The nucleobase is sandwiched by the side-chain of M101
and backbone of S164. In addition, the carbonyl of F163
points toward the uridine ring. The nucleobase recogni-
tion is due to a hydrogen-bond network involving
carbonyl of L160 (2.9A ˚ from N3), the amide of M158
(3.0A ˚ from O4) and the hydroxyl of T168. The latter
points toward C5 (3.7A ˚ ), which is also closed to the Ca
from G157 (3.5A ˚ ) leaving no space for a halide atom
except ﬂuoride, in agreement with our biochemical data.
The O2 atom is not hydrogen bonded but is in van der
Waals contact with the Cd of P161 and the Cg of the
aspartate D97. The latter is hydrogen-bonded to the O20
hydroxyl group of the ribose. In addition, the ribose is in
van der Waals contacts with G77, G83 and G100. Finally,
the two phosphate groups are hydrogen-bonded to
the side chains of K36 (2.6A ˚ ), R82 (Ne1-PaO=3.3A ˚
and NZ1-PbO=2.5A ˚ ) and T165 (Og1-PaO=2.7A ˚ )
and the backbone amines of G39 and G77.
In the ﬁve other monomers the UMP sites are totally
empty with no trace of any bound nucleotide and the
segment 81–89 adopts an ‘open’ conformation. This con-
formation corresponds mainly to a re-orientation of the
helical segment 81–89 as observed in UMPKec
(PDB2BND versus PDB2V4Y). The ‘open’ conformation
is also observed in most other bacterial UMPKs (usually
co-crystallized without UMP, UDP or UTP). The
improved diffraction and, simultaneously, the occupation
of only one site out of six were rather surprising. The UDP
bound to UMPKmt is likely due to 5I-UTP degradation,
as no trace of halide could be detected in the electron
density in the vicinity of the bound UDP. The absence
of iodo substituent is in agreement with the absence of
enzyme activity with 5Br-UMP (see above). Meanwhile,
several attempts to soak UMPKmt crystals with UMP at
millimolar concentration were detrimental for the diffrac-
tion power. This suggested that crystal packing con-
straints were incompatible with simultaneous occupancy
of all the six UMP sites in the hexamer while the (very)
low concentration of UDP in our successful soaking led to
only one bound molecule of this nucleotide per hexamer.
Six GTP molecules (one per monomer) were clearly
visible in the electron density (Figure 4A). They adopt a
similar orientation and one main conformation although
some ﬂexibility in the position of the phosphate groups is
evident in two monomers. The observed conformation
corresponds to that described for ATP in the B. anthracis
UMPK and GTP in X. campestris UMPK (PDB3EK5),
Nucleic Acids Research,2011, Vol.39, No. 8 3465Figure 4. Structure of UMPKmt complexed with GTP. (A) Ribbon representation of the UMPKmt hexamer viewed down the trimeric axis.
The three front monomers are shown in red, brown and green, while their rear dimeric counterparts are partially transparent. The GTP molecules
are shown as sticks (CPK colors) with the electron density in cyan at a 0.9s level. (B). Bacterial UMPKs sequences (acronyms provided on the left)
are aligned to the UMPKmt region interacting with GTP. Strictly conserved residues in all sequences are boxed in black and conserved residues
are bordered. Since each UMPKmt monomer interacts with two GTP molecules, the residues contacting the ﬁrst GTP molecule are labelled by
ﬁlled circles, and the residues contacting the second one by opened circles. P139 in UMPKmt is highlighted by a star. (C). Zoom in of the
GTP-binding site of one UMPKmt monomer (ribbon representation). The two contacting GTP molecules are shown as sticks. The basic residues
contacting the phosphate moiety of the effector are depicted in blue. Residues in grey participate in a hydrogen bond network organizing
the GTP binding site. The hydrophobic residues (P136, L138 and L140) contacting the nucleobase are depicted in pink. Residue P139 is shown
in green.
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appears unique. Most of the interactions between
UMPKmt and GTP involved residues from a short
stretch in the protein sequence (residues 131–150;
Figure 4B and C), although for each GTP molecule
there are interacting residues from two monomers
related by the three-fold axis. From one monomer, four
basic residues (R123, R141, K148 and R150) protrude to
interact with the negatively charged phosphate groups and
with the ribose (R123). The ribose is also hydrogen
bonded to the side chain of E135, whereas the guanine
moiety interacts through hydrogen bonds with backbone
atoms of G131 and Q132. The Cd of P136 appears in close
contact ( 3.3A ˚ ) with the carbonyl group of the base
moiety suggesting that a partial and weak hydrogen
bond is also formed. In parallel, a second monomer
provides additional interactions. The guanine ring is sand-
wiched by the two hydrophobic side-chains of L1380 and
L1400. Finally, R1440 also points its positively charged side
chain toward the phosphate groups of the same GTP
molecule.
The conformation of the trinucleotide seems further
stabilized by an internal hydrogen bond involving an
oxygen of the a-phosphate group and the proton of the
carbon C8. This close contact (3.2A ˚ ) explained the select-
ivity against 8-bromo-GTP. Conversely, few interactions
are seen with the hydroxyl groups of the ribose moiety in
agreement with the observed binding of dGTP and
mantGTP. The presence of numerous positively charged
arginines and lysines lining the effector binding site ex-
plained the weaker afﬁnity of GMP, GMPPCP and
GMPPNP. While other trinucleotides can partially
mimic the bound GTP molecules, some of the observed
interactions with the nucleobase can discriminate the
possible effectors. ATP binding would be prevented in
UMPKmt because of a close contact between P136 hydro-
phobic side-chain and the charged N6 amino group of the
adenine. Conversely, there is enough room to accommo-
date 5-iodo and 5-bromo-UTP although it is not obvious
what favourable contact would be formed between the
protein and these nucleotides. In the case of UTP, very
few contacts are predicted to occur with the nucleobase
and the loop G131–P136 without local rearrangement.
This structural feature roughly matches the observed
afﬁnity for the halide derivatives of the natural negative
effector UTP (see above).
This structure provided us with a better insight into the
binding mode of the positive effector. In parallel, the con-
formational changes upon GTP binding appeared to be
rather small according to the structural comparisons with
the other bacterial UMPKs structures solved so far with
and without effectors (RMSD around 1.1A ˚ ±0.3).
Hexamers of UMPKmt and X. campestris UMPK
(PDB3EK5) bound to GTP were superposed with the
apo-form of S. pyogenes (PDB1Z9D) and H. inﬂuenzae
(PDB2A1F) UMPKs. While very few changes are
detected near the GTP binding site and the 3-fold axis,
the relative orientation of the ATP binding site seemed
to be slightly affected (Supplementary Figure S4). To
better evaluate this change, we measure the distance
between the Ca of a well-conserved threonine (T257 in
UMPKmt) buried in the C-terminal domain from two
facing monomers. In UMPKmt and X. campestris
UMPK, the distance is  38.4 and 40.4A ˚ , respectively
compared to 42.4 and 43.6A ˚ in the apo-forms (in
H. inﬂuenzae and S. pyogenes UMPKs, respectively).
A similar trend can be deduced from the comparison of
GTP-bound and UDP-bound forms of E. coli UMPK
(PDB2V4Y and PDB2BND, respectively) with distances
T237–T2370 of 40.5 and 43.7A ˚ , respectively. Clearly, a
small but common re-orientation of the ATP-binding
domain is observed upon GTP binding. This is further
conﬁrmed by small-angle X-ray scattering (SAXS) meas-
urements acquired on UMPKmt alone or in presence of
GTP, ATP, UTP or 5I-UTP (Supplementary Figure S5).
Similar curves were obtained in the range of
0.004<q<0.35 and nearly identical curves for small
angle (0.01<q<0.10) for all the tested samples. These
observations extend to higher angles (up to 0.3) for the
apo-enzyme and the protein in the presence of the negative
effector. Conversely, the ATP and GTP bound protein
showed slight differences with the other samples in the
range 0.1<q<0.3. Little change in the deduced radius
of gyration was detected (Rg   42±2A ˚ ). These data sug-
gested a conservation of the quaternary structure and the
global shape of the protein whatever the allosteric effector
bound. A small change in domain orientation and/or sta-
bility is likely triggered by activator binding. A rather
subtle modiﬁcation in dynamic behaviour is also likely
but further experiments would be necessary to shed
more light on the allosteric mechanism.
Characterization of UMPKmt variants obtained by
site-directed mutagenesis
Site-directed mutagenesis was used to validate the bio-
chemical and structural data. A structural rearrangement
affecting the UMP binding site was predicted by our com-
parative models. Two residues were mutated: R82 and
F81 to probe the active site conﬁguration. They were re-
spectively modiﬁed to a histidine or a tryptophan, in the
light of former studies on the E. coli UMPK (71,73) and of
our sequence analysis (see alignment in Figure 3). A third
position, S96, was modiﬁed to an alanine in the context of
the F81W variant, as the model anticipated interactions in
the simple mutant that could affect the local conform-
ational change observed upon substrate binding. Finally,
to get a better insight into the effector binding sites, three
positions (D113, P139 and R150) were selected based on
recent reports (71,72) and from our structure. Besides the
substitution by a tryptophan found in some Gram-
negative bacteria UMPKs, P139 was also mutated to his-
tidine and alanine to discriminate between a removed
backbone constraint and a possible occurrence of a
hydrogen bond by the side-chain nitrogen of the trypto-
phan (and the histidine). The two other residues were
mutated to alanine.
The different variants expressed in E. coli were puriﬁed
following the same procedure as described for the wild-
type UMPKmt, and their oligomerization state checked
by equilibrium sedimentation. Their kinetic parameters
were determined as a function of the concentration of
Nucleic Acids Research,2011, Vol.39, No. 8 3467either UMP (Table 3), or Mg-ATP with or without the
effectors (Figures 5, 6, S6 and S7, Table 2).
As for the wild-type protein, the activity of all the
variants versus UMP concentration followed the
Michaelis–Menten equation. The R82H speciﬁc activity
was drastically reduced (0.7% of the wild-type speciﬁc
activity), whereas for the other variants between 10%
and 75% of the wild-type activity was observed. D113A
displayed the most altered Km
UMP (Table 3). Similarly, the
mutant F81W and R82H showed a decreased afﬁnity for
UMP (3- and 4.5-fold, respectively). On the other hand,
the other mutants exhibit a similar (R150A) or a better
(3- to 8.5-fold) afﬁnity for UMP.
Except for the R150A variant (Supplementary
Figure S6) which displayed general features similar to
the wild-type UMPKmt in any condition, the dependence
of the activity as a function of the second substrate con-
centration revealed striking differences between the
mutants (Table 2, Figures 5, 6 and S7). In particular,
two P139 variants departed from the other mutants. The
P139A variant appeared nearly insensitive to both effect-
ors, whereas the P139W variant exhibit Michaelien
kinetics even in the presence of UTP (Figure 6). In the
absence of any effector, the curves obtained for the differ-
ent variants with Mg-ATP as variable substrate were
hyperbolic, with nH close to 1, except for the F81W/
S96A and R150A variants. However, the afﬁnity for
ATP in most of the variants was in the same range as
that of the wild-type enzyme (Table 2). The two exceptions
were the P139W and the P139H variants with opposite
behaviour: a 3-fold decrease and a 5-fold increase of the
K0.5 for Mg-ATP. Interestingly, the activation by GTP
was abolished for the F81W, R82H, D113A and P139A
variants, leading to unchanged K0.5 for ATP in the
presence of the effector (Table 2, Figures 5, 6 and S7).
The P139W variant was slightly activated by the
addition of 1mM GTP (factor of 1.5 versus 3.5 for the
WT at 1mM ATP and UMP), whereas the D113A was
inhibited up to 50 % in the same conditions (data not
shown). On the other hand, the inhibition by UTP is
retained for most of the variants with IC50 between 0.15
and 0.3mM (data not shown). Again, the P139W plot
(Figure 6) showed a loss of cooperativity and the P139A
variant exhibited a weak effect of the effector on the
afﬁnity for ATP (Table 2).
DISCUSSION
A multi-disciplinary approach was used to study the last
uncharacterized NMPK from M. tuberculosis, namely
UMPKmt. As shown by kinetic experiments on the
wild-type enzyme, UMPKmt behaves as a Gram-positive
bacterial UMPK with cooperativity toward the phosphate
donor ATP and an inhibition by UTP, independent of the
UMP or divalent ion concentrations (51). The Gram-
positive UMPK pattern of the M. tuberculosis enzyme
was also conﬁrmed by the effects of effector analogues,
in particular the halogenated derivatives. However, no
inhibition by excess of UMP was observed as seen for
B. subtilis or S. pneumoniae UMPKs. Another point
worth mentioning is the minor effect of the activator on
the afﬁnity for ATP, as, in the absence of GTP, the K0.5
for ATP of UMPKmt is in the same range than the
supposed physiological concentration of this nucleotide
in mycobacteria. Therefore, the relative concentration of
the pools of purine and pyrimidine nucleotides might be
the major factor responsible of the regulation of the
UMPKmt activity in mycobacteria. The retro-inhibition
of bacterial UMPKs by UTP is not surprising as end
products are usually involved in the regulation of meta-
bolic pathways. The identity of the positive effector is
more intriguing but might be rationalized by taking into
account the general role of GTP and UTP in translation
and transcription in bacteria (74).
To better understand the biochemical and kinetic
properties of UMPKmt, 3D-structure determination was
carried out, along with a validation by mutational
analysis. Sequence similarities with well-characterized bac-
terial orthologues allowed molecular modelling of its
structure and active site using X-ray structures solved in
various ligand states (apo or substrate bound, inhibitor or
activator bound enzymes) (24,25,68,71,72). Among our
predictive results, some correspond to ﬁne local dynamical
behaviour. A structural rearrangement was predicted to
occur around the F81 residue upon binding of UMP.
These alternating conﬁgurations explain the observed be-
haviour of the F81W and F81W S96A variants. The
double mutant F81W S96A was expected to stabilize
one of the two orientations of the tryptophan by
removing a potential hydrogen bond between serine 96
and the introduced tryptophan. Indeed, the afﬁnity for
UMP of the F81W S96A variant was enhanced by a
factor of 7 and 18 compared to the wild-type and the
single mutant, respectively. Accordingly, the tryptophan
side-chain seems to be stabilized in an orientation favour-
able to the binding of UMP by the introduction of the
polar serine. These results revealed the robustness and
the usefulness of our models, despite the fact that they
failed to provide additional clues for the identiﬁcation of
the GTP or UTP binding sites. On the other hand, as
analysis of the regulation of activity by GTP (activator)
and UTP (inhibitor) revealed variations among the bac-
terial enzymes (22,26,51,66,69,75), the allosteric behaviour
of one orthologue appeared barely predictable from
another despite an overall high sequence identity.
The activator binding site has recently been identiﬁed by
X-ray crystallography for three bacterial UMPKs
(68,71,72), and now UMPKmt (this study). All these
structures revealed that the activator binding pocket is
located at the trimer interface, a unique feature among
the AA-kinases. In these UMPKs (but not in E. coli
UMPK), the allosteric effector interacts with a short
region of around 30 residues. The phosphate moieties
are in interaction with four positive residues, mainly ar-
ginines (R123, R141, K148 and R150 in UMPKmt).
Therefore, it is not surprising that the mutation of a
single residue (R150A variant) has almost no effect on
the enzyme properties. The other residues involved in
the binding of the ribose and the nucleobase moieties
are also conserved, except in E. coli UMPK (71), whose
GTP binding pocket seems to be unique. In this UMPK,
3468 Nucleic Acids Research, 2011,Vol.39, No. 8Figure 6. P139W, P139H and P139A variant activity versus Mg-ATP concentration. The concentrations of effectors were 2mM GTP (light blue),
0.5mM GTP (dark blue), no effector (red), 0.5mM UTP (dark green), 1mM UTP (light green) and 2mM UTP (gold green). Same conditions as
Figure 1.
Figure 5. F81W and F81W S96A variant activity versus Mg-ATP concentration. The concentrations of effectors were 0.5mM GTP (dark blue),
1mM GTP (light blue), no effector (red), 0.2mM UTP (dark green) and 1mM UTP (light green). Same conditions as Figure 1.
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W119), and the reorientation of the side-chain of the tryp-
tophan is observed upon GTP binding. This tryptophan is
replaced by an arginine or a proline in many
Gram-positive UMPKs (P139 for UMPKmt). Even if
this residue does not directly interact with the bound
GTP molecule in UMPKmt, its mutation to an alanine
leads to a loss of GTP activation while retaining normal
enzymatic activity level. Two other modiﬁcations have
detrimental effects on the cooperativity properties of the
UMPKmt variants (P139W and P139H). Therefore, P139
is a key element in the allosteric regulation of UMPKmt
and might serve as a sensor of the effector binding at the
trimeric interface. Indeed, it interacts with residues lying
on the loop connecting the N- and C-terminal domains
(Supplementary Figure S8). This loop is predicted by
normal mode analysis to correspond to a hinge region
(data not shown). Furthermore, it also corresponds to
the end of the a-helix bearing polar residues conserved
in most UMPKs and pointing into the catalytic centre,
especially T165 and D166. This helix also bears two
conserved (R149 and E152 in UMPKmt) residues
directly in contact with the conserved Y137 to form an
intricate network of interactions midway from the GTP
binding site, the UMP binding site and the catalytic
centre. Slight rearrangement or stabilization of the
GTP-binding segment and the nearby secondary struc-
tures may affect the entire active site without dramatic
change of the global structure.
Nature has developed various strategies to control and
regulate the activity of proteins. Cooperativity between
different subunits of an oligomeric protein is one of
them (76,77). Ligand binding at one site induced struc-
tural changes that are transmitted to distal active site(s)
and enable ﬁne tuning of activity in response to slight
changes in substrate concentration. In addition to this
long-range cross-talk communication between subunits,
recent work highlighted the role of dynamics in allosteric
regulation (78). Indeed, the allosteric mechanism of the
related AA-kinases has been recently connected to slow
motions by normal mode analysis (79). This study
pointed out a hinge between the N- and C-terminal
domains in agreement with our present results
(Supplementary Figure S8). Further analysis might be ne-
cessary to gain further insight into the mechanism of allo-
steric regulation of the bacterial UMPKs as the overall
structure seems little affected by the binding of its
positive effectors and only subtle changes can be
described. Meanwhile, this suggested that the particular
evolution of UMPKs is connected to the appearance of
distinct allosteric regulation.
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